司美格鲁肽 (诺和诺德)(Semaglutide (Novo Nordisk)) - 药物靶点：GLP-1R_在研适应症：心脏病，肝纤维化，肺纤维化_专利_临床

概要

基本信息

药物类型

重组多肽

别名

Semaglutide、Semaglutide (Genetical Recombination)、Semaglutide (genetical recombination) (JAN)

+ [29]

靶点

GLP-1R

作用方式

激动剂

作用机制

GLP-1R激动剂(胰高血糖素样肽-1激动剂)

治疗领域

神经系统疾病心血管疾病消化系统疾病+ [7]

在研适应症

非在研适应症

原研机构

在研机构

Gilead Sciences, Inc.Novo Nordisk Canada, Inc.

+ [7]

非在研机构

Merck Sharp & Dohme LLC

权益机构

Novo Nordisk Pharmaceuticals Pty Ltd.

Novo Nordisk A/S

Emcure Pharmaceuticals Ltd.

+ [4]

最高研发阶段批准上市

首次获批日期

美国 (2017-12-05),

2型糖尿病

最高研发阶段(中国)批准上市

特殊审评优先审评 (美国)、加速批准 (美国)、优先审评 (中国)、突破性疗法 (中国)、局长国家优先审评券 (美国)、附条件批准 (加拿大)

登录后查看时间轴

结构/序列

Sequence Code 50953

来源: *****

关联

631

项与司美格鲁肽 (诺和诺德) 相关的临床试验

NCT07586150

/ Not yet recruitingN/AIIT

Personalised Pharmaco-Lifestyle Interventions for Severe Mental Illnesses Enhanced by Digital Health and Immersive Technologies

This randomized, rater-blind, multicenter clinical trial will evaluate whether a personalized pharmaco-lifestyle intervention improves mental functioning in adults with severe mental illness, including schizophrenia, bipolar disorder, or major depressive disorder. Participants will be randomized to either a modular individualized intervention program or a structured psychoeducation control condition. The individualized intervention may include physical exercise, an anti-inflammatory diet, sleep intervention, social prescribing, semaglutide for eligible participants with overweight or obesity, and optional closed-loop transcranial alternating current stimulation for participants with prominent depressive symptoms. The primary outcome is change in the SF-36 Mental Component Summary score from baseline to Month 3.

开始日期2028-10-01

申办/合作机构

Ludwig-Maximilians-Universität München

NCT07430332

/ Not yet recruiting临床2期IIT

Leveraging Semaglutide for Preservation of Beta Cell Function and Restoration of Alpha Cell Function

This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes. The goal of this study is to see if semaglutide can protect beta cell function in this group of people and delay the progression to stage 2 type 1 diabetes.

开始日期2027-09-01

申办/合作机构

Children's Hospital & Medical Center

NCT06977438

/ Not yet recruiting临床4期IIT

Promoting Healthy Children and Youth

The rapid emergence of new and highly effective obesity medications has turned the field of pediatric weight management on its head. Adolescents living with obesity, their caregivers, healthcare providers, healthcare systems, policymakers, and payors are now wondering what role health behavior and lifestyle treatment (HBLT) has in terms of body mass index (BMI) reduction, improvements in quality of life and cardiometabolic health, and mitigating nutritional concerns when medications are used. Is intensive (26+ hours) of HBLT needed or could low intensity HBLT be an equally effective alternative; and if so, for whom? Our proposed project will answer these important questions that arise daily in the clinical setting and will generate critical new insights to guide decision-making for teens with obesity and the stakeholders who care deeply about them.

开始日期2027-01-01

申办/合作机构

University of Minnesota

[+2]

100 项与司美格鲁肽 (诺和诺德) 相关的临床结果

登录后查看更多信息

100 项与司美格鲁肽 (诺和诺德) 相关的转化医学

登录后查看更多信息

100 项与司美格鲁肽 (诺和诺德) 相关的专利（医药）

登录后查看更多信息

364

项与司美格鲁肽 (诺和诺德) 相关的文献（医药）

2026-07-01·FREE RADICAL BIOLOGY AND MEDICINE

Semaglutide ameliorates aortic endothelial cell dysfunction in sarcopenia through the SIRT1/cGAS-STING signaling axis

Article

作者: Zhang, Xin ; Wang, Xinglin ; Huang, Ziteng ; Ye, Xiangming ; Qiao, Gan ; Huang, Ting ; Sun, Weiyue ; Yang, Ping ; Wu, Haoran ; Liu, Yang ; Li, Liyun ; Tang, Linyi

Sarcopenia associated with aging is a significant health issue affecting the quality of life in the elderly, yet research on effective treatments remains insufficient. This study aims to investigate the therapeutic effects and mechanisms of Semaglutide (Sema) in D-gal-induced aging-related sarcopenia and endothelial cell senescence. By establishing D-gal-induced mouse models and human aortic endothelial cells (HAEC), and employing methods such as grip strength tests, ELISA, and immunohistochemistry, the therapeutic efficacy and underlying mechanisms of Sema were systematically evaluated. The results demonstrated that Sema significantly improved grip strength in D-gal-induced mice and reduced serum levels of IL-1β and TNF-α, indicating its protective role against sarcopenia. Furthermore, Sema effectively alleviated endothelial cell senescence and improved endothelial function, with the underlying mechanisms potentially involving the upregulation of SIRT1 expression and inhibition of the cGAS-STING signaling pathway activation. This study systematically reveals, for the first time, the therapeutic potential of Sema in aging-related sarcopenia, especially its protective effect against aortic endothelial senescence, providing new perspectives and evidence for its clinical application.

2026-06-01·BIOETHICS

Ethical Issues Related to the Use of GLP‐1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large

Article

作者: Minerva, Francesca

ABSTRACT:

This paper explores the ethical implications of emerging weight‐loss medications such as Semaglutide (Ozempic) and Tirzepatide (Mounjaro), analysing their therapeutic applications for obesity and potential use as enhancement drugs. These medications promise significant benefits, including improved individual health outcomes, reduced healthcare costs and, potentially, reduced environmental harms. However, their widespread adoption raises various concerns, such as unknown long‐term side effects, the exacerbation of weight‐based discrimination, and the reinforcement of socioeconomic disparities. The paper argues that, with robust regulatory frameworks in place, the potential benefits of these medications are likely to outweigh the risks. Nonetheless, ongoing monitoring of their effect on individuals and society at large remains essential.

2026-06-01·FREE RADICAL BIOLOGY AND MEDICINE

Semaglutide alleviates age-related dry eye disease by restoring lacrimal gland structure and function

Article

作者: Zuo, Xin ; Wang, Yueying ; Chi, Kaiyi ; Zeng, Hao ; He, Yiru ; Yu, Honghua ; Huang, Zhaohao

The prevalence of age-related dry eye disease (DED) is rapidly increasing with global aging, and progressive lacrimal gland (LG) dysfunction represents a central pathogenic mechanism for which targeted therapies remain limited. Semaglutide (Sema), a glucagon-like peptide-1 receptor agonist widely used in metabolic diseases, has recently shown anti-aging effects in multiple tissues, yet its effects on LG aging and age-related DED have not been defined. Here, using a naturally aged mouse model, we show that long-term Sema treatment significantly alleviates DED-related phenotypes and preserves LG structural integrity. High-throughput single-cell transcriptomic analyses revealed that LG aging was characterized by extensive remodeling of cellular composition, loss of acinar cells, expansion of fibroblasts and immune populations, and enhanced intercellular communication, all of which were broadly attenuated by Sema treatment. SenMayo-based profiling demonstrated widespread accumulation of senescent cells across epithelial, stromal, and immune compartments, accompanied by activation of stress-, inflammatory-, and apoptotic transcriptional programs. Sema markedly reduced senescent cell burden and senescence-associated transcriptional activation, consistent with decreased SA-β-gal activity, p21 expression, and SASP-related factors in LGs, and reduced systemic inflammatory cytokines. Mechanistically, Sema exerted cell-type-specific effects by alleviating oxidative stress and enhancing stress adaptation in acinar cells, suppressing extracellular matrix remodeling and pro-fibrotic programs in fibroblasts, and dampening pro-inflammatory and chemotactic activation in macrophages. Together, these findings demonstrate that Sema mitigates age-related LG dysfunction and DED through coordinated attenuation of senescence-associated pathological programs, supporting cellular senescence as a pharmacologically tractable mechanism and highlighting Sema as a potential therapeutic strategy for age-related DED.

13,414

项与司美格鲁肽 (诺和诺德) 相关的新闻（医药）

18 小时之前

·BioSpace

CicadaBio Announces Oral Presentation on CC-18, a First-in-Class GLP-1/ActRII Fusion Protein Designed for Muscle-Preservation Weight Loss, at ADA 2026

New preclinical data demonstrate robust weight reduction, lean mass preservation, durable effects after treatment discontinuation and potential for extended dosing intervals SHANGHAI--(BUSINESS WIRE)--CicadaBio today announced that new preclinical data for CC-18, its investigational GLP-1/anti-ActRII dual-pathway fusion protein, were shared during an oral presentation at the American Diabetes Association (ADA) Scientific Sessions 2026. The data demonstrated robust weight reduction, preservation of lean mass, reduced weight regain following treatment discontinuation and the potential for extended dosing intervals. CC-18 is designed to address a growing challenge in obesity treatment: achieving meaningful weight loss while preserving muscle mass and improving long-term metabolic health. By combining GLP-1 receptor activation with ActRII pathway blockade in a single molecule, CC-18 is designed to reduce excess fat while preserving or potentially increasing lean mass, resulting in more favorable body composition outcomes. While GLP-1-based therapies have transformed the treatment of obesity, increasing attention is being placed on the quality of the weight loss achieved. Clinical studies have shown that a substantial proportion of weight loss achieved with current therapies may come from a reduction in lean body mass. As a result, preservation of muscle mass is increasingly recognized as an important factor for metabolic health, physical function and long-term weight maintenance. Key findings presented at ADA 2026: Diet -induced obesity (DIO) mouse models: Greater weight reduction than semaglutide Significant preservation and increase of lean mass alongside reductions in fat mass, resulting in improved body composition Approximately 58% lower weight regain following treatment discontinuation compared with semaglutide-treated mice In diet-induced obesity mouse models, CC-18 achieved greater weight reduction than semaglutide while preserving and increasing lean mass. Weight loss was driven primarily by reductions in fat mass, and animals treated with CC-18 exhibited approximately 58% less weight regain following treatment discontinuation than semaglutide-treated controls. Non-human primates (NHP) studies: Sustained weight reduction and favorable body composition changes Prolonged pharmacodynamic activity supporting the potential for monthly dosing In non-human primate studies, CC-18 produced sustained reductions in body weight and favorable changes in body composition. The molecule demonstrated prolonged pharmacological activity and durable target engagement supporting the possibility of extended dosing intervals. “These data support our vision that the future of obesity treatment extends beyond simply losing weight,” said Dr. Jia Ni, Chief Executive Officer of CicadaBio. “As the field evolves beyond first-generation GLP-1 therapies, increasing attention is being directed toward approaches that improve body composition, preserve lean mass and support durable outcomes. We believe the next generation of therapies will be defined by high-quality weight loss and the data presented at the ADA meeting reinforce the potential of CC-18 to address several important limitations associated with current obesity treatment.” CC-18 is currently advancing clinical development, including through participation in Lilly’s Catalyze360 initiative, which is supporting clinical proof-of-concept activities and further advancement of the program. ADA 2026 Oral Presentation Details Presentation Title : In Vitro and In Vivo Characterization of CC-18, a Novel GLP-1R/ActRIIA/ActRIIB Dual Pathway-Targeting Fusion Protein That Reduces Weight While Increasing Muscle in Preclinical Models Presenter: Dr. Jia Ni, Founder and CEO, CicadaBio Board No.: 1105 Date: June 5, 2026 Time: 3 PM CDT Location: Room 343 About CicadaBio CicadaBio is a biotechnology company developing innovative therapies for obesity, metabolic disease, and related chronic conditions. The company is focused on advancing differentiated therapeutic approaches that improve both metabolic outcomes and the quality of weight loss through novel biological mechanisms. Contacts Investors: Yan Zhang, MS, MBA Head of Business Development CicadaBio 707-623-7337 yan.zhang@cicadabio.com Media: Lauren Arnold LA Communications Lauren@LACommunications.net

19 小时之前

·药番茄Pharmato

赛诺菲提前终止CIDP药物Riliprubart III期临床试验

6月10日，法国制药巨头赛诺菲（Sanofi）发布公告称，将提前终止其关键在研药物Riliprubart（SAR445088/BIVV020）在慢性炎性脱髓鞘性多发性神经根神经病（CIDP）患者中的III期临床研究（MOBILIZE研究）。此次决策基于独立数据监察委员会（IDMC）的期中分析结果，该委员会判定MOBILIZE研究“极不可能达到预期的疗效终点”。这一消息不仅宣告了该项目在特定患者群体中的折戟，也为赛诺菲原本就备受关注的研发管线平添了一份变数。难治性CIDP的临床博弈：为何MOBILIZE折戟？ CIDP是一种罕见的自身免疫性神经系统疾病，其病理机制在于免疫系统攻击外周神经周围的髓鞘。尽管临床上现有静脉注射免疫球蛋白（IVIg）等标准疗法，但其局限性依然明显：数据显示，约30%的CIDP患者对标准疗法无响应，而在有响应的患者中，约70%的治疗效果为“不完全缓解”，且不到三分之一的患者能在不依赖持续治疗的情况下维持缓解。赛诺菲寄希望于Riliprubart能够改变这一现状。作为一种针对经典补体途径中C1s的IgG4人源化单克隆抗体，Riliprubart旨在通过阻断C1s来抑制驱动脱髓鞘及轴突损伤的核心炎症机制。此前，Riliprubart在II期研究中展现出极佳的潜力，87%的受试者在切换至该药物后病情保持稳定或改善，这曾让外界对其III期临床抱有极高期待。然而，进入III期阶段后，现实与预期出现了温差。MOBILIZE研究原计划招募约140名对免疫球蛋白或皮质类固醇疗法失效的患者，进行为期24周的头对头比较。最终，期中分析的失利促使赛诺菲果断选择止损。研发管线的“动荡之旅”与未来考量赛诺菲明确表示，此次终止MOBILIZE研究不会产生重大财务负担，也不会改变公司2026年的财务指引。目前，公司正与临床研究中心团队紧密配合，确保受试患者的后续护理过渡，并将对MOBILIZE研究收集的全面数据进行深度剖析，以优化后续研究方向。关于Riliprubart的另一项III期临床研究——VITALIZE研究，其命运也面临重新评估。该试验旨在评估Riliprubart在接受IVIg治疗且处于维持期患者中的表现，赛诺菲将综合考虑此次MOBILIZE的结果，审慎决定是否继续该研究。对于赛诺菲而言，这已经是近期研发管线中的又一次波折。近年来，公司在自身免疫和炎症领域的布局频繁遭遇临床挑战，包括： Amlitelimab（抗OX40L抗体）在哮喘II期试验中表现未达预期； Balinatunfib（口服TNF抑制剂）在银屑病中试研究失利； Itepekimab（与再生元合作的IL-33项目）在慢阻肺（COPD）III期研究中出现挫折。竞争格局：补体抑制剂领域的“蝴蝶效应” 赛诺菲此次研发节奏的打乱，也在一定程度上改变了CIDP治疗市场的竞争态势。此前，市场分析师曾预测Riliprubart在2033年有望贡献约4.8亿欧元（约5.55亿美元）的年销售额。随着赛诺菲步伐的放缓，其潜在的竞争对手将面临重新洗牌。目前，Argenx公司的FcRn抑制剂Vyvgart Hytrulo已获FDA批准用于CIDP；与此同时，Dianthus Therapeutics正在进行的C1抑制剂claseprubart III期临床研究也备受关注。Dianthus此前曾指出，尽管赛诺菲的II期数据验证了C1抑制剂在CIDP领域的可行性，但临床上的差异化竞争最终将取决于药物的实际疗效。对于赛诺菲而言，虽然Riliprubart在难治性CIDP群体中的受挫是一次严峻考验，但研发的本质即是不断试错与迭代。在追求“科学奇迹”的道路上，如何从一次次失败中提炼出对补体途径乃至自身免疫系统更深刻的理解，或许是这家医药巨头当下最重要的功课。 --- 以上正文 --- 往期好文《新药价值评估模型 3.0》提示词 MASH 新药竞争格局-2026年3月口服GLP-1竞争格局 JPM值得关注的CNS领域进展：Kv7 钾离子通道诺和诺德：中国最高法院对司美格鲁肽化合物专利作出了积极的裁决报告：肿瘤浸润淋巴细胞（TIL）疗法综述 - 2025年12月 Treg：调节性T细胞（Treg）疗法演进过程、竞争格局（含附件）体内CAR-T：竞争格局全析，交易、管线、主流递送平台 TSLP竞争格局：SHR-1905启动特应性皮炎2期临床报告：FGF21的研究进展-2025年10月报告：T细胞衔接器（TCE）在自身免疫性疾病的研究进展 2026年的创新药，需要关注的重点药番茄追踪新药情报，分享AI在制药领域落地应用，欢迎感兴趣的朋友加群交流。若如上二维码添加失败，也可以添加助理微信进群。声明：本文内容供业内同行交流学习，不代表药番茄表平台立场，不构成任何投资意见和建议。药番茄不对任何主体因使用本文内容而导致的任何损失承担责任。内容如有疏漏，欢迎沟通指出！

2026-06-10

·PRNewswire

The GLP-1 Era: How To Lose Weight Without Losing Muscle

With Nutrishop's support, GLP-1 user loses 70+ pounds of body fat while preserving vital lean muscle FITCHBURG, Mass., June 10, 2026 /PRNewswire/ -- Millions of Americans are turning to GLP-1 medications such as Zepbound®, Wegovy® and Ozempic® to lose weight. In fact, a recent KFF Health Tracking Poll found that approximately 1 in 8 U.S. adults is currently taking a GLP-1 medication. But as the number on the scale drops, health and fitness professionals say many users are unknowingly losing something they shouldn't: lean muscle mass. Continue Reading Valerie Rainville (left) lost more than 70 pounds while preserving lean muscle during her GLP-1 weight-loss journey with nutritional guidance and lifestyle support from Tracey Voyer (right), co-owner of Nutrishop Fitchburg. For Valerie Rainville of Gardner, Massachusetts, preserving muscle while losing weight became a priority from the very beginning of her weight-loss journey. The 59-year-old nurse began taking Zepbound in May 2025 after struggling with her health, low energy levels and stubborn weight gain. At the same time, she began working with Tracey Voyer, co-owner of Nutrishop Fitchburg, to focus on important lifestyle changes, such as increasing her daily protein intake to 150g per day, cutting out added sugars, strength training regularly and walking nearly every day. Within eight months, Rainville dropped from 244 to 168 pounds before eventually stopping Zepbound. She consistently tracked her progress with body composition analysis scans at Nutrishop Fitchburg, allowing her to monitor how much body fat she was losing while maintaining lean muscle mass. By the end of her journey, she had lost over 70 pounds of body fat while preserving nearly all of her lean muscle. "It's important to know that GLP-1s are an aid, not a band-aid," Rainville said. "You have to put in the hard work to be successful. I never would have reached my goal without all the other work that goes with it." Why Muscle Matters During Weight Loss Recent studies have suggested that lean tissue loss may account for 25% to 40% of the total weight lost during GLP-1 treatment. That matters because muscle does far more than simply shape the body. Lean muscle helps support metabolism, strength, balance, mobility, energy levels and healthy aging — all things people need to maintain an active, independent lifestyle as they get older. Losing too much muscle during rapid weight loss can slow down metabolism, leading the body to burn fewer calories at rest. It may also make it harder to maintain long-term weight loss, increasing the risk of rebound weight gain. In some cases, people may lose pounds on the scale but still carry a high body fat percentage, a phenomenon fitness professionals commonly refer to as becoming "skinny fat." Five Ways to Help Protect Muscle During GLP-1 Use Long before GLP-1 medications became mainstream, Nutrishop emphasized the importance of building and preserving lean muscle as part of a healthy weight-loss journey and long-term wellness plan. Today, Voyer continues that approach at Nutrishop Fitchburg, where she partners with a local medical weight-loss clinic that refers GLP-1 patients, including Rainville, for body composition assessments, nutritional guidance and lifestyle support. Based on her experience working with these individuals, Voyer recommends the following strategies for protecting muscle while losing weight: Prioritize protein intake throughout the day to help support muscle maintenance and recovery. Because protein needs vary by individual, Voyer says protein goals should be based on factors such as body composition, activity level and estimated calorie expenditure during weight loss. Incorporate resistance training or strength training several times per week to give the body a reason to hold onto muscle. Stay hydrated and maintain proper electrolyte balance, especially for those experiencing nausea or digestive issues. Track body composition, not just body weight, to better understand how much fat and muscle are being lost throughout the journey. Consider supplements that support muscle preservation and recovery during GLP-1 use, such as protein powders, creatine and amino acids, and targeted muscle-support products like Betabol™ and Peptide 490™. Building Habits That Last Rainville has maintained her weight loss since stopping Zepbound in January. She continues to consume 150 grams of protein daily, walks about 15,000 steps most days and strength trains three times per week. She credits education, accountability and lifestyle changes for helping her achieve lasting results. "I actually thought Tracey was crazy when she first told me how much protein I needed," Rainville admitted. "Now I understand why it mattered." For Voyer, stories like Rainville's highlight what she believes is the most important lesson for anyone considering GLP-1 medications. "When taking a GLP-1, it is extremely important to learn about proper nutrition," she said. "People can lose weight on these medications, but long-term success still comes down to building healthier habits for life." For more information about protecting lean muscle during weight loss, visit NutrishopUSA.com or stop by your local Nutrishop store. ABOUT NUTRISHOP® Founded in 2003, Nutrishop has become one of the nation's most trusted names in health, wellness and dietary supplements, helping individuals achieve their health and fitness goals through real support and real results. With franchisee-owned stores across the U.S., Nutrishop offers exclusive product lines, body composition assessments and nutritional guidance. Committed to exceptional service and meaningful community impact, Nutrishop empowers customers to live stronger, healthier lives while giving entrepreneurs the tools and ongoing support to build successful, purpose-driven businesses. For more information, visit NutrishopUSA.com and follow @NutrishopUSA on Instagram. To learn about franchise opportunities, visit NutrishopFranchise.com. SOURCE Nutrishop 21% more press release views with Request a Demo

100 项与司美格鲁肽 (诺和诺德) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10025	司美格鲁肽 (诺和诺德)	A10BJ06	DB13928

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
心脏病	英国	Novo Nordisk A/S	2026-04-01
肝纤维化	美国	Novo Nordisk, Inc.	2025-12-22
肺纤维化	加拿大	Novo Nordisk Canada, Inc.	2025-12-21
心血管疾病	美国	Novo Nordisk, Inc.	2025-08-15
代谢功能障碍相关脂肪性肝炎	美国	Novo Nordisk, Inc.	2025-08-15
代谢功能障碍相关脂肪性肝炎	美国	Novo Nordisk A/S	2025-08-15
慢性肾病	美国	Novo Nordisk A/S	2025-01-28
慢性肾病	美国	Novo Nordisk, Inc.	2025-01-28
脑卒中	澳大利亚	Novo Nordisk Pharmaceuticals Pty Ltd.	2024-12-16
心肌梗塞	加拿大	Novo Nordisk Canada, Inc.	2024-11-27
肥胖	美国	Novo Nordisk, Inc.	2021-06-04
超重	美国	Novo Nordisk, Inc.	2021-06-04
2型糖尿病	美国	Novo Nordisk, Inc.	2017-12-05

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
白蛋白尿	临床3期	加拿大	Novo Nordisk A/S	2022-03-14
白蛋白尿	临床3期	德国	Novo Nordisk A/S	2022-03-14
白蛋白尿	临床3期	荷兰	Novo Nordisk A/S	2022-03-14
白蛋白尿	临床3期	西班牙	Novo Nordisk A/S	2022-03-14
膝关节炎	临床3期	美国	Novo Nordisk A/S	2021-10-01
膝关节炎	临床3期	加拿大	Novo Nordisk A/S	2021-10-01
膝关节炎	临床3期	哥伦比亚	Novo Nordisk A/S	2021-10-01
膝关节炎	临床3期	丹麦	Novo Nordisk A/S	2021-10-01
膝关节炎	临床3期	法国	Novo Nordisk A/S	2021-10-01
膝关节炎	临床3期	挪威	Novo Nordisk A/S	2021-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05813912 (CTgov)	临床3期	2型糖尿病	148	Semaglutide+Insulin Icodec	鏇餘範遞醖範糧齋膚選(遞鬱觸積繭獵鏇選鏇製) = 繭壓構願鏇衊網繭膚鏇範願觸襯窪遞膚願鏇範 (壓膚網繭獵簾鹹餘夢鏇, 0.86) 更多	-	2026-06-03
NCT05813925 (REDEFINE 5, Pubmed \| Lancet Diabetes Endocrinol)	临床3期	超重	331	Cagrilintide-semaglutide	願獵廠範齋範壓壓齋醖(醖壓鹽鹹繭構襯鏇廠構) = 窪鹽衊範窪構鹹襯鹽獵艱願淵觸廠壓簾製鏇餘 (糧積膚鏇願醖鹽獵淵獵 )	积极	2026-06-01
				Semaglutide	願獵廠範齋範壓壓齋醖(醖壓鹽鹹繭構襯鏇廠構) = 淵鏇膚鹽築積衊襯糧鹽艱願淵觸廠壓簾製鏇餘 (糧積膚鏇願醖鹽獵淵獵 )
NCT06041217 (STEP12, CTgov)	临床3期	肥胖	242	Placebo	鏇憲遞顧築鹽憲醖襯醖(製壓積遞獵齋網夢築鑰) = 鏇繭繭夢鏇構顧蓋選夢糧餘齋鑰淵蓋積觸餘餘 (鏇遞製觸獵壓蓋壓廠窪, 5.4) 更多	-	2026-05-18
NCT05514535 (CTgov)	临床3期	2型糖尿病 \| 肥胖	573	Semaglutide+Insuline glargine U100 (reduced) (Insuline Glargine U100 (Reduced) + Semaglutide)	鏇憲憲齋窪鹹積壓鹽壓(獵餘鹹窪鹹窪願製襯憲) = 膚鹽製憲遞鬱獵繭積膚顧構製遞構獵齋壓選範 (廠窪糧鏇餘範鹽憲淵鏇, 0.84) 更多	-	2026-05-11
				Insuline glargine U100 (titrated) (Insuline Glargine U100 (Titrated))	鏇憲憲齋窪鹹積壓鹽壓(獵餘鹹窪鹹窪願製襯憲) = 餘蓋夢齋廠構鏇網簾鹽顧構製遞構獵齋壓選範 (廠窪糧鏇餘範鹽憲淵鏇, 0.92) 更多
NCT05035095 (OASIS 1, CTgov)	临床3期	肥胖	667	Semaglutide (Oral Semaglutide 50 mg)	構簾蓋鏇網艱鹹願淵餘(膚廠壓廠遞繭醖範鏇遞) = 築窪窪衊築網範衊淵製窪積壓遞願構壓膚鑰襯 (糧蓋膚夢鹹遞遞鏇鹹壓, 10.3) 更多	-	2026-05-07
				placebo+semaglutide (Placebo)	構簾蓋鏇網艱鹹願淵餘(膚廠壓廠遞繭醖範鏇遞) = 範糧願艱構顧壓醖鑰鏇窪積壓遞願構壓膚鑰襯 (糧蓋膚夢鹹遞遞鏇鹹壓, 7.2) 更多
NCT03914326 (SOUL, Pubmed \| JAMA Cardiol)	临床3期	2型糖尿病	9,650	Oral Semaglutide	鑰齋膚艱獵簾範餘餘構(夢鏇廠夢繭繭艱簾壓願) = 積網網鹹鏇積艱製廠夢鑰廠網遞觸鏇壓廠鬱淵 (艱製餘鑰繭構網醖襯壓, 1.01 ~ 1.02) 更多	积极	2026-05-01
NCT07227948 (Pubmed \| BMJ Open)	临床2期	药物滥用	75	Semaglutide	艱鹽鏇窪壓膚繭醖糧顧(簾願鬱窪鏇網窪艱齋壓) = 築構淵構蓋築鑰憲鏇膚鹹獵網遞鑰選繭鬱糧壓 (繭餘簾齋製構簾選築繭 ) 更多	积极	2026-05-01
NCT05649137 (STEP UP T2D, CTgov)	临床3期	2型糖尿病 \| 肥胖	512	Semaglutide (Semaglutide 7.2 mg)	網鏇選鑰鑰鑰鹽觸鹹壓(鏇膚選構衊簾鹹壓餘餘) = 夢鏇衊獵遞憲鑰憲鑰憲鏇窪鬱蓋襯網鑰壓鑰醖 (鬱壓窪鑰鏇獵窪壓廠淵, 8.7) 更多	-	2026-04-27
				Semaglutide (Semaglutide 2.4 mg)	網鏇選鑰鑰鑰鹽觸鹹壓(鏇膚選構衊簾鹹壓餘餘) = 簾廠遞積糧醖壓觸顧鬱鏇窪鬱蓋襯網鑰壓鑰醖 (鬱壓窪鑰鏇獵窪壓廠淵, 8.1) 更多
NCT05646706 (STEP UP, CTgov)	临床3期	肥胖	1,407	Semaglutide (Semaglutide 7.2 mg)	糧網鹽鑰鏇製夢壓蓋餘(構遞糧構遞選壓鏇襯築) = 壓選餘構蓋網觸窪餘膚鑰衊艱壓夢蓋遞醖鹽獵 (築鬱獵選鑰蓋壓廠鹹鏇, 10.6) 更多	-	2026-04-23
				Placebo (Placebo)	糧網鹽鑰鏇製夢壓蓋餘(構遞糧構遞選壓鏇襯築) = 蓋窪衊簾鬱鏇顧築鹹獵鑰衊艱壓夢蓋遞醖鹽獵 (築鬱獵選鑰蓋壓廠鹹鏇, 7.1) 更多
NCT05144984 (CTgov)	临床2期	2型糖尿病	500	Placebo (NNC080-0389)+Semaglutide	衊鹽觸淵醖願窪艱襯繭(醖衊築鏇選廠鏇築顧鹹) = 鏇願艱鏇餘選齋膚網淵廠鏇夢鹽繭網網壓範願 (齋糧鑰窪範廠膚憲窪願, 0.9) 更多	-	2026-04-09